The Riverside Company, a global private investor focused on the smaller end of the middle market, has invested in Rockpointe, Inc., a premier healthcare education company. Rockpointe is a provider of accredited continuing education activities and related training for healthcare professionals. The acquisition is an add-on to Riverside’s portfolio company Clinical Education Alliance (CEA).
Rockpointe develops educational materials that are delivered either virtually or in-person and primarily generates revenue through grants from customers such as pharmaceutical sponsors, with no cost to training attendees. The company’s multi-channel offerings include regional events, online education and webinars across high-science therapeutic areas including oncology, immunology, infectious diseases, and cardiology.
“We are delighted to join forces with the leadership team at Rockpointe,” said Riverside Capital Appreciation Fund (RCAF) Co-Chief Investment Officer Peter Tsang. “This company brings a strong Primary Care audience – an area that CEA has been looking to expand into – as well as added scale in high-growth, high-science therapeutic areas.”
The acquisition of Rockpointe is the second add-on for Riverside’s CEA platform, following the purchase of MDOutlook, a provider of precision intelligence solutions that help life sciences companies develop and commercialize therapeutics and diagnostics in oncology, in July 2021.
Working alongside Tsang and Riverside Vice President Mark Fishman on the investment for Riverside were Partner Jason Fulton, Associate Abeer Irfan, Associate Peter Muncey, Operating Partner J.P. Fingado. Operating Finance Executive David Kralic and Capital Markets Senior Partner Anne Hayes. Regional Director Origination, Will Davis, sourced the investment for Riverside.